Articles From: AbbVie raises 2015 outlook to Abengoa Recognized as CDP Leader for Its Transparency in Climate Change Management


AbbVie Inc. (ABBV) on Thursday raised its 2015 earnings outlook and said it will further refine numbers as the launch of its Hepatitis C treatment progresses.
Sign-up for AbbVie raises 2015 outlook investment picks
AbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of Chronic Genotype 1 Hepatitis C Canada NewsWire MONTREAL , Dec.
Sign-up for AbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of Chronic Genotype 1 Hepatitis C investment picks
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure - Tolerability profile shows more than 98 percent of patients completed a full course of therapy - All-oral interferon-free regimen also approved for HCV/HIV-1 co-infection and patients who have undergone a liver transplant NORTH CHICAGO, Ill.
Sign-up for AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C investment picks
- Reports Third-Quarter Adjusted EPS of $0.89, Up 8.5 Percent and Well Above the Previous Guidance Range of $0.77 to $0.79; Reports GAAP EPS of $0.31 - Significantly Raises 2014 Adjusted EPS Guidance Range to $3.25 to $3.27 from $3.06 to $3.16 (GAAP EPS Guidance Range is $1.15 to $1.17); 2014 Guidance Excludes Any Potential HCV Revenue - Delivers Revenue of $5.019 Billion, an Increase of 7.8 Percent Over Third-Quarter 2013 (Up 8.3 Percent On an Operational Basis); Revenue Up 13.5 Percent Operationally Excluding Lipid Sales - Revenue Growth Reflects 17.5 Percent Global Sales Growth from HUMIRA (Up 17.8 Percent on an Operational Basis) and Strong Growth from Other Key Products - Continues to Expect U.S. Approval of HCV Combination in 2014; Announced Novel R&D Collaboration with Calico to Develop Medicines for Age-Related Diseases; Further Strengthened Pipeline with Global Collaboration to Develop and Commercialize Duvelisib, PI3K-Inhibitor for Treatment of Cancer
Sign-up for AbbVie Reports Third-Quarter 2014 Financial Results investment picks
AbbVie Inc. (ABBV) shares climbed more than 2% in premarket trade Friday, after the biopharma company's third-quarter profit and sales beat estimates.
Sign-up for AbbVie shares up 2% as profit, sales beat estimates investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Host Fourth-Quarter and Full-Year 2014 Earnings Conference Call investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Credit Suisse 2014 Healthcare Conference investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Jefferies 2014 Global Healthcare Conference investment picks
Data from 13 accepted abstracts include: - New Results from a Phase 2 Study of Venetoclax (formerly ABT-199/GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) - Several Studies of Elotuzumab in Patients with Multiple Myeloma, Including Final Results from a Phase 1b/2 Study - Results from Phase 1 studies of Duvelisib in Patients with Chronic Lymphocytic Leukemia NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting investment picks
- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis - Data underscore AbbVie's commitment to evaluating treatments across a range of patients with chronic hepatitis C virus infection BOSTON , Nov.
Sign-up for AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 investment picks
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response rates 12 weeks post-treatment (SVR(12)) of 93.5 percent after 12 weeks of treatment and 90.6 percent after 24 weeks of treatment, respectively - In adult liver transplant patients with recurrent chronic GT1 HCV infection and new to treatment after transplantation, CORAL-I demonstrated 97.1 percent SVR rates at 12 and 24 weeks post-treatment after 24 weeks of treatment - CORAL-I results published online today in The New England Journal of Medicine BOSTON , Nov.
Sign-up for AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 investment picks
By Michael Calia Combination of Viekirax and Exviera already has U.S. approval AbbVie Inc. (ABBV) said Friday that European regulators approved the sale of the company's hepatitis C treatment.
Sign-up for AbbVie's hepatitis C drug gets European approval for sale investment picks
- 37 abstracts evaluating HUMIRA and investigational medicines in rheumatologic diseases - New data presented on ABT-122, an investigational novel protein that targets TNF and IL-17 NORTH CHICAGO, Ill.
Sign-up for AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab) investment picks
Axalta Coating Systems (NYSE: AXTA), a leading supplier of liquid and powder coatings, has received certification in accordance with NSF/ANSI 61: Drinking Water System Components – Health Effects standards for its Abcite ® thermoplastic powder coatings, which are used in a wide variety of industrial applications including pipes and fittings for drinking water systems.
Sign-up for Abcite Receives NSF/ANSI 61 Certification for Use in Drinking Water System Components investment picks
2015/1/21
The plant will have a capacity to desalinate 60,000 m 3 of seawater per day and will supply the local community.
Sign-up for Abengoa and AWT to Develop the World's First Solar-Powered Desalination Plant, in Saudi Arabia investment picks
It lays the foundation for the development of large water projects for 2015 WASHINGTON, Dec.
Sign-up for Abengoa and Daelim Sign a Memorandum of Understanding for the Development of Water Projects investment picks
2014/12/9
The world's leading power companies—according to ENR—have signed a strategic collaboration agreement.
Sign-up for Abengoa and Hyundai E&C Sign a Memorandum of Understanding to Collaborate on Power Plants investment picks
2014/12/11
WASHINGTON, Dec.
Sign-up for Abengoa Announces Plans for Sale of Shares of Abengoa Yield investment picks
2015/1/15
WASHINGTON, Jan.
Sign-up for Abengoa Announces the Pricing of the Secondary Public Offering of Its Shares of Abengoa Yield investment picks
2015/1/19
Ignacio Garcia Alvear, current CFO of Abengoa Bioenergy is appointed as Co-CFO for Investor Relations & Capital Markets, effective February 1st, 2015.
Sign-up for Abengoa Appoints Co-CFO Responsible for Investor Relations & Capital Markets investment picks
2014/12/18
The company will generate the power from a combination of solar-thermal and photovoltaic plants.
Sign-up for Abengoa Awarded 950 GWh/Year in Chilean Supply Tender for 15 Years investment picks
2014/10/17
U.S. Secretary of Energy Dr.
Sign-up for Abengoa Celebrates Grand Opening of Its First Commercial-Scale Next Generation Biofuels Plant investment picks
2014/12/12
The total investment in the project is US$ 640 million, to be developed in a 3-year construction term and a 22-year operation period.
Sign-up for Abengoa Completes Its Non Recourse Long Term Financing for the El Zapotillo Aqueduct in Mexico investment picks
2014/11/21
The project, worth approximately €23 million, will enable part of the country's energy demand to be supplied in an efficient and sustainable way.
Sign-up for Abengoa is Awarded New Power Transmission Project in Morocco investment picks
2014/11/12
Strong business performance: double digit growth in EBITDA (24 %) and net income (38 %). Healthy contracting activity leading to backlog of 7,305 million euros.
Sign-up for Abengoa Presents Its Results for the First Nine Months of 2014 investment picks
2014/10/28
The report includes the 125 largest listed companies in Spain and Portugal (Iberia) that have demonstrated a committed strategy to climate change.
Sign-up for Abengoa Recognized as CDP Leader for Its Transparency in Climate Change Management investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: AbbVie raises 2015 outlook to Abengoa Recognized as CDP Leader for Its Transparency in Climate Change Management
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent